Actively Recruiting
Impact of Nasal Antisepsis with 10% Povidone Iodine on Candida Auris Colonization
Led by Mary K Hayden · Updated on 2025-10-15
120
Participants Needed
3
Research Sites
104 weeks
Total Duration
On this page
Sponsors
M
Mary K Hayden
Lead Sponsor
R
Rush University Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the effect of using 10% povidone iodine nasal antisepsis on the detection of Candida auris, a type of yeast that can colonize the nose and skin and contaminate the environment. This open-label, randomized, controlled trial focuses on patients in acute care and nursing home settings to assess whether nasal antisepsis can reduce colonization and environmental contamination with C. auris. The study is important due to the safety profile of povidone iodine and its previous use against other bacteria in the nose.
CONDITIONS
Brief Title
Nasal Antisepsis for C. Auris Prevention
Who Can Participate
Eligibility Criteria
You may qualify if you...
- History of Candida auris colonization or infection
- Patient in a participating healthcare facility
You will not qualify if you...
- History of severe allergy to iodine-based products, including anaphylaxis or rash
- Currently breastfeeding or pregnant
- Non-English speaking
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 days
Participants who test positive for C. auris colonization at screening are randomly assigned to receive intranasal povidone iodine twice daily for up to 5 days or no intranasal treatment (control).
5 visits during the intervention week
Duration - Up to 8 weeks or until facility discharge
Participants are monitored with sample collection once weekly after the intervention until discharge or up to 8 total study visits after randomization.
Up to 3 weekly visits after the intervention week
Trial Site Locations
Total: 3 locations
1
Rush University Medical Center
Chicago, Illinois, United States, 60612
Actively Recruiting
2
RML Specialty Hospital
Chicago, Illinois, United States, 60624
Actively Recruiting
3
RML Specialty Hospital
Hinsdale, Illinois, United States, 60521
Actively Recruiting
Research Team
S
Sarah E. Sansom, DO
M
Mary K. Hayden, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here